- Alvotech and Dr. Reddy’s Enter Into Collaboration for Commercialization of AVT03 (denosumab), a Biosimilar Candidate to Prolia® & Xgeva® in the U.S., Europe and UK
- Dr. Reddy’s Q4 & Full Year FY24 Financial Results
- Dr. Reddy's Laboratories Announces the Launch of Doxycycline Capsules, 40 mg* in the U.S.
- Dr. Reddy's Laboratories launches Versavo® (bevacizumab) in the UK
Key statistics
On Thursday, Dr Reddy's Laboratories Ltd (DRREDDY:NSI) closed at 5,897.70, -9.35% below its 52-week high of 6,505.90, set on Feb 28, 2024.
52-week range
Open | 5,902.45 |
---|---|
High | 5,933.00 |
Low | 5,835.00 |
Bid | 5,900.00 |
Offer | 5,897.70 |
Previous close | 5,897.70 |
Average volume | 392.98k |
---|---|
Shares outstanding | 166.53m |
Free float | 118.39m |
P/E (TTM) | 17.55 |
Market cap | 977.98bn INR |
EPS (TTM) | 334.61 INR |
Annual div (ADY) | 40.00 INR |
---|---|
Annual div yield (ADY) | 0.68% |
Div ex-date | Jul 11 2023 |
Div pay-date | Aug 26 2023 |
Data delayed at least 15 minutes, as of May 23 2024 11:28 BST.
More ▼